Top Markets
Coin of the day
Bright Minds Biosciences Inc. Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

DRUG
Rang in Aktien #11319
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Aktienkurs
$73.12
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$715.61M
Veränderung (1 Tag)
-1.90%
Veränderung (1 Jahr)
88.01%
Land
US
Handel Bright Minds Biosciences Inc. (DRUG)

Kategorie

Dividendenrendite-Verlauf für Bright Minds Biosciences Inc. (DRUG)
Dividendenrendite (TTM) von Bright Minds Biosciences Inc. (Aktienkürzel: DRUG) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Bright Minds Biosciences Inc. (DRUG) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH